Key Highlights

  • The net loss for the third quarter of 2026 was $144.8 million.
  • Research and development expenses were $134.6 million, compared with $59 million a year earlier.
  • Cash, cash equivalents and short-term investments totaled $1.2 billion at September 30, 2026.
  • The highest dose group showed up to a 16.2% mean reduction in body weight at 72 weeks.

Structure Therapeutics (NASDAQ:GPCR) reported a net loss of $144.8 million for the third quarter of 2026, compared with $65.7 million for the same period in 2025. Research and Development expenses were $134.6 million and cash, cash equivalents and short-term investments totaled $1.2 billion at September 30, 2026. The company also reported data showing up to a 16.2% mean reduction in body weight in its highest dose group at 72 weeks.

Operating Expenses

Research and development expenses for the third quarter of 2026 were $134.6 million, compared with a lower amount in the prior-year quarter. General and administrative expenses were $21.8 million, compared with a lower amount in the prior-year period. The company reported non-cash share-based compensation expense as part of its net loss.

The net loss for the quarter was $144.8 million, compared with $65.7 million in the third quarter of 2025. The non-cash share-based compensation expense for the prior-year quarter was $7.5 million, according to the company's comparison.

Cash Position

Cash, cash equivalents and short-term investments totaled $1.2 billion as of September 30, 2026. The company's Balance Sheet presents the amounts by category, and the prior-period comparison is included in its report.

Clinical Data

The company reported data showing a mean reduction in body weight of up to 16.2% in its highest dose group at 72 weeks. The company reported that treatment discontinuation rates due to treatment-emergent adverse events were less than 5% at its starting dose, according to the update.

The company described the data as coming from its clinical study. The complete data set, including the placebo comparison, is presented in the company's full clinical report.

Final Word

Structure Therapeutics reported a third-quarter 2026 net loss of $144.8 million, research and development expenses of $134.6 million, general and administrative expenses of $21.8 million and cash and short-term investments of $1.2 billion. The company reported up to a 16.2% mean body weight reduction at 72 weeks in its highest dose group.